![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase III Randomized Study of Octreotide in Preventing or Reducing the Severity of Chemoradiotherapy-Induced Diarrhea in Patients With Anal or Rectal Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Published Results Trial Contact Information Registry Information
Alternate Title
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase III | Supportive care | Closed | 18 and over | RTOG-0315 NCT00075868 |
Objectives Primary - Determine the ability of octreotide to prevent the incidence of moderate, severe, or life-threatening chemoradiotherapy-induced diarrhea (grades 2-4) in patients with anal or rectal cancer.
Secondary - Compare the quality of life of patients treated with this drug vs placebo.
- Compare the number of hospitalizations and use of antidiarrheal agents (e.g., Imodium®) related to diarrhea (or its complications) in patients treated with these drugs.
- Compare treatment delays and/or dose reductions (chemotherapy and radiotherapy) in patients treated with these drugs.
Entry Criteria Disease Characteristics:
- Histologically confirmed primary anal or rectal cancer
- No metastasis beyond the pelvic regional nodes
- Must be scheduled to receive chemoradiotherapy
Prior/Concurrent Therapy:
Biologic therapy Chemotherapy - See Disease Characteristics
- Prior chemotherapy allowed
Endocrine therapy - At least 6 months since prior administration of any of the following:
- Glucocorticoid therapy
- Insulin sensitizers (e.g., metformin, pioglitazone, or rosiglitazone)
- Exogenous growth hormone therapy
Radiotherapy - See Disease Characteristics
- No prior pelvic radiotherapy
- No prior intensity-modulated radiotherapy
- No concurrent radiotherapy for abdominal cancer
- No concurrent hyperfractionated, split-course, or intensity-modulated radiotherapy
- No brachytherapy prior to or after completion of all external beam radiotherapy
Surgery - No prior abdominal-perineal resection or other surgical procedure leaving the patient without a functioning rectum
- No colostomy
Other - More than 30 days since other prior investigational drugs
- No prior octreotide for cancer therapy-related diarrhea
- No concurrent prophylactic antidiarrheal medication
Patient Characteristics:
Age Performance status Life expectancy Hematopoietic Hepatic - Liver function tests < 3 times upper limit of normal
- No prior hepatic disease
Renal Gastrointestinal - No prior chronic or acute regional enteritis
- No malabsorption syndrome
- No prior inflammatory bowel disease that may exacerbate the radiotherapy toxicity
- No grade 2 or greater uncontrollable diarrhea at baseline
- No prior cholecystitis or gallstones, unless a cholecystectomy has been performed
- No prior incontinence of stool
Other - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No uncontrolled diabetes (e.g., fasting glucose > 250 mg/dL)
- No prior allergy or hypersensitivity to study drug or other related drug or compound
- No other medical condition or mental impairment that would preclude study treatment and compliance
Expected Enrollment A total of 226 patients (113 per treatment arm) will be accrued for this study within 2 years. Outcomes Primary Outcome(s)Prevention of the incidence of moderate, severe, or life-threatening diarrhea
Secondary Outcome(s)Quality of life Economic measures Validity of the Functional Alterations due to Changes in Elimination-Changes in Bowel Function, the Quality of Life-Radiation Therapy Instrument, and the Expand Prostate Index Composite-Bowel questionnaires Prevention of the incidence of severe or life-threatening (i.e., grade 3-5) diarrhea
Outline This is a double-blind, placebo-controlled, randomized, multicenter study. Patients are stratified according to radiotherapy dose (< 50 Gy vs ≥ 50 Gy), chemotherapy dose (bolus vs continuous), and gender. Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive octreotide* intramuscularly (IM) 4-7 days before the start of chemoradiotherapy and on day 22 (± 3 days) during chemoradiotherapy.
- Arm II: Patients receive placebo* IM 4-7 days before the start of chemoradiotherapy and on day 22 (± 3 days) during chemoradiotherapy.
[Note: *Patients receive a total of 2 injections of octreotide or placebo] In both arms, treatment continues in the absence of unacceptable toxicity. Quality of life is assessed at baseline, at the completion of chemoradiotherapy, and at 3, 6, 9, and 15 months from the start of chemoradiotherapy. Patients are followed at 3, 6, 9, and 15 months from the start of chemoradiotherapy. Published ResultsZachariah B, James J, Gwede CK, et al.: RTOG 0315: a randomized, double-blind, placebo-controlled phase III study to determine the efficacy of octreotide acetate in preventing or reducing the severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer. [Abstract] J Clin Oncol 25 (Suppl 18): A-4032, 2007.
Trial Contact Information
Trial Lead Organizations Radiation Therapy Oncology Group ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Babu Zachariah, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Jaffer Ajani, MD, Protocol co-chair | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2003-12-10 | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00075868 | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2003-12-09 | ![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2006-02-27 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](https://webarchive.library.unt.edu/eot2008/20090513095035im_/http://www.cancer.gov/images/spacer.gif) |